Menu Search
Equities

Mabpharm Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2181:HKG.HS

Mabpharm Ltd

Actions
  • Price (HKD)0.51
  • Today's Change0.00 / 0.00%
  • Shares traded18.00k
  • 1 Year change+75.86%
  • Beta0.8247
Data delayed at least 15 minutes, as of Feb 11 2026 07:33 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)479.44m
  • Net income in HKD-31.08m
  • Incorporated2018
  • Employees383.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.